Related Experiment Video
Updated: Aug 30, 2026

Optogenetic Activation of Afferent Pathways in Brain Slices and Modulation of Responses by Volatile Anesthetics
Published on: July 23, 2020
Propofol regulates SLC6A2 expression via NAT10-mediated ac4C modification to modulate excessive mitophagy and
1Department of Anesthesiology, The Affiliated Lianyungang Hospital of Xuzhou Medical University, No.6 Zhenhua East Road, Haizhou District, Lianyungang City, 222002, Jiangsu Province, China.
Abstract:
Postoperative cognitive dysfunction (POCD) is a common complication in elderly patients, and propofol exposure has been implicated in its pathogenesis. This study investigated whether propofol exacerbates hippocampal neuron dysfunction via N4-acetylcytidine (ac4C) modification mediated by N-acetyltransferase 10 (NAT10). HT22 cells were treated with propofol to assess cytotoxicity, inflammation, oxidative stress, and mitophagy. The NAT10/SLC6A2 interaction was validated using ac4C RNA immunoprecipitation (RIP), RNA pull-down, and dual-luciferase reporter assays. A POCD model was established by tibial fracture surgery in C57BL/6 J mice. Cognitive function was evaluated using Morris water maze and Y-maze tests. Propofol treatment upregulated SLC6A2 and NAT10 expression in HT22 cells (P < 0.05). Knockdown of SLC6A2 attenuated propofol-induced cytotoxicity, apoptosis, inflammation, oxidative stress, mitochondrial depolarization, and excessive mitophagy (P < 0.05). Mechanistically, NAT10 directly bound to SLC6A2 mRNA and induced ac4C modification of SLC6A2 mRNA, enhancing its stability. Overexpression of SLC6A2 reversed the protective effects of NAT10 knockdown (P < 0.05). In addition, the NAT10/SLC6A2 axis mediated propofol-induced activation of the NF-κB pathway (P < 0.05). In aged POCD mice, knockdown of SLC6A2 improved cognitive performance and reduced neuroinflammation, oxidative stress, and excessive mitophagy (P < 0.05). Propofol promotes excessive mitophagy and hippocampal neuron dysfunction in aged POCD via the NAT10-mediated ac4C modification-dependent upregulation of SLC6A2. Targeting SLC6A2 may represent a potential therapeutic strategy for POCD.
